Fig. 6. Atractylodes lancea and atractylodin activate the AMPK signaling pathway. (A) Molecular docking model of atractylodin binding to AMPK. The α subunit is represented in purple, the γ subunit in beige, and the components in yellow. (B, C) Cell viability after Atractylodes lancea (left) or atractylodin treatment (right). HepG2 cells were treated with Atractylodes lancea or atractylodin for 24 h at the indicated doses. The MTT assay was performed, and absorbance at 540 nm OD was measured (n=5). (D, E) Protein levels of phospho-AMPK and phospho-ACC. HepG2 cell were treated with (D) Atractylodes lancea (n=8) or (E) atractylodin (n=3) at the indicated concentrations for 3 h. Data are presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA with Dunnett’s post-hoc test. *p<0.05, ***p<0.001: compared with Control; N.S., not significant.
© Biomolecules & Therapeutics
